Informations générales (source: ClinicalTrials.gov)

NCT02810262 Statut inconnu
Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer (POUMOS) (POUMOS)
Observational
  • Adénocarcinome pulmonaire
  • Adénocarcinome
  • Maladies de la moelle osseuse
  • Tumeurs osseuses
  • Tumeurs du poumon
  • Métastase tumorale
  • Seconde tumeur primitive
Hospices Civils de Lyon (Voir sur ClinicalTrials)
juin 2011
décembre 2019
29 juin 2024
Mortality due to non small cell lung cancers is the first cause of cancer death in men around the world. Lung adenocarcinoma regularly induces bone metastases responsible for high morbidity and impaired life quality. Overall survival of these patients is poor. Thus the investigators aimed to identify if some bone and metabolic parameters were associated with overall survival. Patients and Methods POUMOS is a prospective cohort of patients suffering from adenocarcinoma lung cancers with a first bone metastasis (stage IV). All patients have a bone biopsy with molecular status characterization of the tumor for EGFR, KRAS, BRAF and ALK. Bone metastasis localizations are obtained by bone scintigraphy or FDG-PET/CT. Whole body composition is obtained by DEXA scan (Hologic®). The investigators assessed also fasting blood levels of bone and metabolic biomarkers. Survival analyses will be performed using a proportional hazard regression model.
 Voir le détail

Etablissements

Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Hospices Civils de Lyon - Hôpital Edouard Herriot - Centre des Métastases Osseuses (CEMOS) - 69003 - Lyon - France Cyrille Confavreux, MD, PhD En recrutement Contact (sur clinicalTrials)

Critères

Tous
Inclusion Criteria:

- adults over 18 years

- both gender

- covered by the French National Insurance

- first bone metastases of adenocarcinoma lung cancer (synchronous or metachrone)


- adenocarcinoma previously treated by systemic oncologic treatment (chemotherapy,
targeted therapy, immunotherapy)